New EC nod for Rybrevant

The European Commission (EC) has approved a Type II extension of indication for Johnson & Johnson’s (NYSE: JNJ) Rybrevant (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed).

Adding to previous lung cancer approvals, the combination has now been approved for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

It is the first treatment regimen to show significant improvement in progression-free survival compared to chemotherapy alone in this patient population.